The Journal Of Dermatological Treatment[JOURNAL]
Sun
200 papers
A novel non-steroidal treatment approach for moderate Atopic dermatitis in a 13-month-old infant using SNEPI: a case report.
Yang CJ, Park SH, Lee D … +9 more , Kim SH, Kim M, Lee JH, Kim SJ, Kim TS, An KH, Kim EA, Oh HJ, Seong JW
J Dermatolog Treat · 2025 Dec · PMID 40968562 · Publisher ↗
OBJECTIVES: Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects an...
OBJECTIVES: Atopic dermatitis (AD) is a chronic inflammatory skin condition with increasing prevalence in infancy. Standard treatments rely heavily on topical corticosteroids, but concerns about long-term side effects and limited efficacy in some cases highlight the need for alternative therapeutic strategies. METHODS: We present a 13-month-old male with moderate AD refractory to moisturizers and hydrocortisone ointments. Sympathetic Nerve Entrapment Point Injection (SNEPI) was administered bilaterally at the T7 paraspinal level using 1 mL of normal saline once weekly for three sessions. Clinical outcomes were monitored during treatment and over a six-year follow-up period. RESULTS: Pruritus resolved and sleep normalized after the first treatment. By the third session, complete remission of skin lesions was achieved without corticosteroid use, with no recurrence observed during four weeks of follow-up. During a six-year follow-up, the child maintained stable skin with only occasional mild pruritus, suggesting sustained therapeutic benefit. CONCLUSIONS: This case demonstrates the potential of SNEPI as a safe, effective, and steroid-free neuromodulatory treatment for pediatric AD, supporting the role of autonomic modulation in inflammatory skin disorders. Further clinical studies are warranted to evaluate the broader applicability of SNEPI in pediatric dermatology.
Apremilast in the treatment of pityriasis lichenoides et varioliformis acuta: a case report.
Zhou J, Jing M, Liu M … +3 more , Fang L, Yang L, Qiao G
J Dermatolog Treat · 2025 Dec · PMID 40964939 · Publisher ↗
OBJECTIVES: To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms. METHODS: We...
OBJECTIVES: To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms. METHODS: We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated. RESULTS: Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up. CONCLUSIONS: Apremilast may be a safe and effective option for refractory PLEVA.
TNF-alpha inhibitor therapy for granuloma annulare.
Afzal N, Burney W, Sivamani RK
J Dermatolog Treat · 2025 Dec · PMID 40960077 · Publisher ↗
BACKGROUND: Granuloma annulare (GA) is an inflammatory cutaneous reaction characterized by erythematous, annular skin lesions. The etiology of GA is unknown, and treatment is challenging. The current treatment options in...
BACKGROUND: Granuloma annulare (GA) is an inflammatory cutaneous reaction characterized by erythematous, annular skin lesions. The etiology of GA is unknown, and treatment is challenging. The current treatment options include topical or intralesional steroids. Biologics can also be effective. METHODS: In this paper, we review the current literature on the use of TNF-alpha inhibitor therapy in the treatment of GA. RESULTS/CONCLUSION: GA has a positive response to TNF-alpha inhibitors, most notably with etanercept and adalimumab. These findings can aid dermatologists in treating GA that is unresponsive to other therapies.
Amorolfine hydrochloride cream and 2% crisaborole ointment: a study on their therapeutic benefits for keratotic tinea pedis.
Du N, Yang J, Lv X … +2 more , Wang Y, Min W
J Dermatolog Treat · 2025 Dec · PMID 40936384 · Publisher ↗
The clinical effectiveness of 2% crisaborole cream and amorolfine hydrochloride cream on keratinized tinea pedis is the goal of this investigation. Using random numbers, 100 patients with keratotic tinea pedis were spli...
The clinical effectiveness of 2% crisaborole cream and amorolfine hydrochloride cream on keratinized tinea pedis is the goal of this investigation. Using random numbers, 100 patients with keratotic tinea pedis were split into two groups: the observation group received 2% crisaborole ointment and amorolfine hydrochloride cream once a night for four weeks, while the control group received white vaseline and amorolfine hydrochloride cream once a night. The two groups were compared in terms of clinical efficacy, adverse reaction incidence, and improvement in the dermatological quality of life index (DLQI) score. Following four weeks of treatment, the observation group's overall effective rate was 98%, which was significantly higher than 82%, and the difference was statistically significant ( < 0.001). The pruritus scales were (6.12 ± 1.92) days, (12.01 ± 3.89) days, (3.92 ± 3.02) days, and (15.09 ± 3.98) days in the control group. The observation group was significantly lower than the control group at both the 2-week and 4-week treatment points ( < 0.001). The incidence of negative effects did not differ significantly between the two groups ( > 0.05). For keratinized tinea foot, 2% crisaborole ointment can increase the effectiveness of amorolfine hydrochloride cream.
It is still a secret disease - clinical images in randomized controlled trials on hidradenitis suppurativa.
Lindsø Andersen P, Jemec GB, Polesie S
J Dermatolog Treat · 2025 Dec · PMID 40936220 · Publisher ↗
PURPOSE: Hidradenitis suppurativa (HS) is a recalcitrant, chronic, inflammatory skin disease characterized by painful nodules, abscesses, and tunnels, primarily affecting intertriginous areas. Despite its substantial neg...
PURPOSE: Hidradenitis suppurativa (HS) is a recalcitrant, chronic, inflammatory skin disease characterized by painful nodules, abscesses, and tunnels, primarily affecting intertriginous areas. Despite its substantial negative impact on patients' quality of life, HS has been historically understudied. Recently, an increasing number of randomized controlled trials (RCTs) have expanded treatment options and informed clinical guidelines. While quantitative data using clinical scoring systems is standard to disseminate RCT results, this study aimed to assess the extent of clinical image dissemination, as this can increase transparency and support layperson communication. MATERIALS AND METHODS: A systematic review was performed on 265 identified articles, of which 37 met the inclusion criteria. Each trial was evaluated for the inclusion of clinical images and the number of patients represented. RESULTS: Clinical images were included in 15 of 37 trials (40.5%), depicting only 33 of 4,327 randomized patients (0.7%) across 90 photos. Articles published before 2020 more frequently included photos than those published later ( = 0.008). The low inclusion rate of clinical photos in HS RCTs is, however, slightly higher than in comparable psoriasis and atopic dermatitis studies. CONCLUSIONS: Given dermatology's visual nature, the limited use of clinical photos in HS RCTs is notable. Increasing clinical photo dissemination in scientific articles may enhance research transparency, aid young physicians' education, and improve patient communication. However, standardized photo protocols and ethical considerations are essential for implementation.
Dupilumab for Hailey-Hailey disease.
Debeuf MPH, Vlaanderen P, van Geel M … +2 more , Steijlen PM, Verstraeten VLRM
J Dermatolog Treat · 2025 Dec · PMID 40936211 · Publisher ↗
AIM: Hailey-Hailey disease is a rare autosomal dominant blistering disease predominantly affecting the skinfolds. Due to the clinical heterogeneity and lack of guidelines, diagnosis and treatment is challenging. At prese...
AIM: Hailey-Hailey disease is a rare autosomal dominant blistering disease predominantly affecting the skinfolds. Due to the clinical heterogeneity and lack of guidelines, diagnosis and treatment is challenging. At present, there is an increasing use of biologicals in the treatment of HHD. However, their efficacy varies. METHODS: This case report describes the therapeutic effect of dupilumab in combination with benzathine benzylpenicillin in a 49-year-old woman with extensive therapy-resistant Hailey-Hailey disease. RESULTS: After a follow-up period of eight months, we observed a marked improvement of the Hailey-Hailey plaques, and the patient's quality of life improved. A minor relapse occurred after 15 months, possibly due to an emotionally stressful event for the patient. No adverse events were reported. CONCLUSION: Our case report illustrates the benefit of combining dupilumab and benzathine benzylpenicillin for extensive, therapy-resistant HHD. However, long-term complete remission remains challenging and sustained psychological support seems advised.
Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial.
Zhu C, Feng B, Pan J … +3 more , Ma J, Hu B, Liu L
J Dermatolog Treat · 2025 Dec · PMID 40931395 · Publisher ↗
BACKGROUND: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD). OBJECTIVES: This post hoc analysis evaluated the impact of early itch relief...
BACKGROUND: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD). OBJECTIVES: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients. METHODS: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed. Patients were classified as early itch responders (EIR; ≥4-point reduction in Worst Itch Numeric Rating Scale at week 4) or non-early itch responders (non-EIR). Outcomes included the Dermatology Life Quality Index (DLQI) total score, DLQI 0/1 response rate, DLQI work/study item, and the Patient-Oriented Eczema Measure (POEM) sleep item. RESULTS: Of 225 patients, 90 were EIR and 135 were non-EIR. The EIR group showed significantly greater improvements in DLQI total score, DLQI 0/1 response rate, and work productivity from week 4 through week 52 compared to the non-EIR group. Sleep disturbance due to itch was also significantly improved in the EIR group from week 4 to week 40, though the difference at week 52 was not statistically significant. CONCLUSIONS: Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
Dupilumab monotherapy in super-elderly patients with bullous pemphigoid: a retrospective study on long-term efficacy and safety in mild to moderate cases.
Fang X, Gong Q, Zhou Y … +6 more , Lv H, Han Z, Yang K, Zhang Q, Bao Y, Fu Y
J Dermatolog Treat · 2025 Dec · PMID 40931388 · Publisher ↗
BACKGROUND: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly...
BACKGROUND: Bullous pemphigoid (BP) is a common autoimmune subepidermal bullous disease. Dupilumab, an IL-4/IL-13 inhibitor, represents a novel therapeutic approach for BP, but real-world long-term data in super-elderly patients are limited. METHODS: This retrospective, single-center observational study included super-elderly BP patients (≥80 years) receiving dupilumab monotherapy from September 2022 to September 2024. Disease severity was assessed using BPDAI and NRSP, and BP180 antibody, total IgE, and eosinophil count were monitored over 52 weeks. RESULTS: Thirteen patients with mild to moderate BP were enrolled. Ten (76.9%) achieved Complete remission (CR) within a mean of 7.4 weeks. BPDAI and NRSP significantly improved, with BPDAI scores decreased from 16.08 ± 9.00 at baseline to 1.23 ± 1.64 at week 16 and 0.23 ± 0.44 at week 52 (both < 0.001). BP180 and total IgE also showed significant improvement. Two patients experienced relapse after discontinuing treatment. Comorbidities were generally well managed, though three patients passed away due to worsening comorbidities. One patient experienced mild drowsiness and erythema; no other dupilumab-related adverse events were observed. CONCLUSION: Dupilumab demonstrates significant long-term efficacy and safety in super-elderly BP patients (≥80 years) with mild to moderate disease and multiple comorbidities, offering a promising alternative to traditional therapies.
Teledermatological services at a Swiss university hospital - evaluation of patient benefits and economic impact .
Beck J, Goncalves De Lira R, Maul LV … +5 more , Anzengruber F, Brockes C, Meier-Schiesser B, Braun RP, Greis C
J Dermatolog Treat · 2025 Dec · PMID 40928012 · Publisher ↗
OBJECTIVES: The aim of this study is to evaluate the potential of online consultation services in a Swiss dermatological clinic as a tool for triage, focusing on time savings, patient satisfaction, and cost-effectiveness...
OBJECTIVES: The aim of this study is to evaluate the potential of online consultation services in a Swiss dermatological clinic as a tool for triage, focusing on time savings, patient satisfaction, and cost-effectiveness. METHODS: Over a period of 30 months, data were generated from a publicly available store-and-forward teledermatological platform (www.derma2go.com) hosted by the Dermatology Department of the University Hospital Zurich (USZ) for this analytical observational retrospective single-center study. Anonymized metadata from the online consultations and evaluation forms, as well as data from optional in-person follow-up consultations were analyzed. RESULTS: Data were collected from 2207 patients (mean age 39.4 years, 51.2% female). The three most common diagnoses were atopic dermatitis, acne vulgaris, and perioral dermatitis/rosacea. 89.3% rated their satisfaction with the service at 7 or higher out of 10. The median waiting time for responses by dermatologists was 13.4 h. The service was financially profitable. CONCLUSIONS: Our study investigated the potential benefits of incorporating teledermatology into the services offered by a Swiss university hospital. It was a valuable tool to reduce waiting times and costs while achieving a high level of satisfaction. These findings can aid hospitals in choosing cost-effective and patient-friendly teledermatological services.
Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.
Niki M, Kamata M, Tada Y … +1 more , Kubo Y
J Dermatolog Treat · 2025 Dec · PMID 40916222 · Publisher ↗
OBJECTIVES: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and sa...
OBJECTIVES: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors. METHODS: We analyzed data from 27 AA patients treated with baricitinib at our hospital. RESULTS: The majority (81%) had alopecia universalis, with a mean baseline SALT score of 93.9. Disease duration was positively correlated with the current AA episode's duration and negatively with serum TARC levels. At 3, 6, 9, and 12 months, 3.8%, 19.2%, 37%, and 58% of patients achieved a SALT score ≤20, respectively. The duration of the current AA episode at initiating baricitinib was correlated positively with absolute SALT score at 6 and 9 months, and negatively with the reduction rate of SALT score at 6 and 9 months. A shorter duration of the current episode (<4 years) was associated with better improvement in SALT scores at 6, 9, and 12 months compared to longer durations (≥4 years). CONCLUSIONS: Baricitinib proved effective and safe for severe AA patients. The duration of the current AA episode is a key predictor of treatment success, highlighting the importance of early intervention.
Social determinants of health, quality of life, and productivity outcomes among adults with vitiligo in Brazil, China, India, and South Africa.
Kurosky SK, Atkinson C, Jagun O … +11 more , Cooper C, Lejeune A, Castellano G, Reynolds N, Llamado L, Makgoeng S, de Castro CCS, Parsad D, Raboobee N, Gao XH, Lemeshow AR
J Dermatolog Treat · 2025 Dec · PMID 40916214 · Publisher ↗
OBJECTIVES: Vitiligo is an autoimmune disease resulting in skin depigmentation and individuals report substantial psychosocial burden. However, vitiligo-related quality of life impacts appear heterogeneous and may be inf...
OBJECTIVES: Vitiligo is an autoimmune disease resulting in skin depigmentation and individuals report substantial psychosocial burden. However, vitiligo-related quality of life impacts appear heterogeneous and may be influenced by social determinants of health. This cross-sectional survey aimed to describe characteristics and vitiligo-related quality of life impacts among adults in Brazil, China, India, and South Africa. METHODS: Results were stratified by country and examined by bivariate analysis. RESULTS: Respondents ( = 2202) were mean (standard deviation) 36.9 (11.5) years of age. The most frequently reported income quartile was the highest quartile in China, India, and South Africa, and second-lowest quartile in Brazil. Mean time since initial diagnosis was 11.7 years. Mean % body surface area with depigmentation ranged from 3.7% (China) to 9.7% (South Africa). Mean Dermatology Life Quality Index scores ranged from 5.8 in Brazil to 10.3 in India, indicating a 'moderate' effect of vitiligo on quality-of-life; for 32.3% of respondents, vitiligo had a 'very-to-extremely large' impact on quality-of-life. Mean daily activity impairment was 28.9%. Employed participants reported mean work impairment of 35.6%. Adults with vitiligo in Brazil, China, India, and South Africa reported diverse demographic, socioeconomic, and clinical characteristics. CONCLUSIONS: Overall, vitiligo had a moderate impact on quality of life and was associated with reduced work productivity and activity impairments.
Abrocitinib combined with low-dose corticosteroids in the management of tattoo-related cutaneous sarcoidosis: a case report.
Geng Q, Xu J
J Dermatolog Treat · 2025 Dec · PMID 40904315 · Publisher ↗
PURPOSE: Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a...
PURPOSE: Sarcoidosis is a chronic, multisystem granulomatous disorder characterized histologically by non-caseating granulomas. Despite the availability of various therapeutic options, long-term disease control remains a significant clinical challenge. MATERIALS AND METHODS: We report the case of a 55-year-old female diagnosed with sarcoidosis. Skin and lymph node biopsies revealed non-caseating granulomatous inflammation, and chest CT indicated pulmonary involvement. Infectious causes of granulomatous disease, including Mycobacterium tuberculosis, non-tuberculous mycobacteria, and fungal infections, were excluded through com-prehensive testing. The patient initially received conventional systemic corticosteroid therapy but developed treatment-related complications. Due to the need for sustained disease control, an alternative regimen combining low-dose corticosteroids with the selective JAK1 inhibitor abrocitinib was initiated. RESULTS: The patient showed significant clinical improvement following the combination therapy, with no observed treatment-related adverse events. CONCLUSIONS: This case suggests that low-dose corticosteroids combined with a JAK1 inhibitor such as abrocitinib may represent a treatment option for patients with sarcoidosis.
Rapid and sustained response to tofacitinib in a patient with anal pyoderma gangrenosum under immunosuppression and bone marrow suppression.
Zhou Y, Zhang L, Wang W
J Dermatolog Treat · 2025 Dec · PMID 40904272 · Publisher ↗
AIM: To evaluate the therapeutic efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of refractory perianal pyoderma gangrenosum (PG) under conditions of baseline immunosuppression and b...
AIM: To evaluate the therapeutic efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of refractory perianal pyoderma gangrenosum (PG) under conditions of baseline immunosuppression and bone marrow suppression. METHODS: We present a 62-year-old male with a 4-month history of painful, progressive symmetrical perianal ulcerations diagnosed as PG, coexisting with condyloma acuminatum. The patient had a background of pure red cell aplasia and myasthenia gravis, and was undergoing chronic immunosuppressive therapy with prednisolone and tacrolimus. Previous interventions including topical agents, antibiotics, phototherapy, and surgical debridement were ineffective. Oral tofacitinib (5 mg/day) was introduced following multidisciplinary evaluation. RESULTS: Marked pain reduction was achieved by day two of tofacitinib therapy, with near-complete ulcer healing observed within two weeks. Hematologic parameters remained stable throughout the 4-month treatment course, which was well tolerated with no adverse effects. The patient remained relapse-free during a 1-year follow-up. CONCLUSIONS: Tofacitinib may offer a rapid, effective, and well-tolerated treatment alternative in cases of refractory PG, even when layered onto preexisting immunosuppressive regimens. This case highlights the potential of JAK inhibitors as targeted therapy in complex PG presentations and supports their further clinical evaluation.
Successful guselkumab treatment for a psoriasis patient experiencing an adrenal crisis: a case report.
Luo N, Shen Y, Su L … +1 more , Hao P
J Dermatolog Treat · 2025 Dec · PMID 40856381 · Publisher ↗
PURPOSE: Prolonged glucocorticoid therapy may lead to adrenal insufficiency (AI) or even adrenal crisis (AC) due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis. METHODS: This case report describes a male...
PURPOSE: Prolonged glucocorticoid therapy may lead to adrenal insufficiency (AI) or even adrenal crisis (AC) due to suppression of the hypothalamic-pituitary-adrenal (HPA) axis. METHODS: This case report describes a male patient with psoriasis who had received long-term irregular glucocorticoid therapy for psoriasis management. Following an upper respiratory tract infection, the patient developed generalized skin lesions accompanied by systemic symptoms including abdominal pain, vomiting, fatigue, fever, and lethargy. After multiple misdiagnoses, the patient was ultimately diagnosed with psoriasis complicated by AC. RESULTS: The patient was subjected to guselkumab combined with glucocorticoid therapy for the treatment of psoriasis and AC. After 6 months, complete resolution of skin lesions was achieved, and adrenal function returned to normal. CONCLUSIONS: Dermatologists should be aware of the potential for AI when prescribing glucocorticoids (topical or systemic) to treat psoriasis. Guselkumab represents a viable therapeutic option for psoriasis patients with concurrent AI/AC.
Observational study on postoperative JAK inhibitor and corticosteroid therapy following non-cultured epidermal cell suspension transplantation in stable vitiligo patients.
Zhang Y, Xu Y, Cui W … +4 more , Ding X, Gu Y, Zhang X, Li M
J Dermatolog Treat · 2025 Dec · PMID 40832814 · Publisher ↗
OBJECTIVE: To compare the efficacy and safety of oral corticosteroids and JAK inhibitors as adjunctive treatments following non-cultured epidermal cell suspension (NCES) transplantation in patients with stable vitiligo....
OBJECTIVE: To compare the efficacy and safety of oral corticosteroids and JAK inhibitors as adjunctive treatments following non-cultured epidermal cell suspension (NCES) transplantation in patients with stable vitiligo. METHODS: Data were collected from 12 patients with stable vitiligo who underwent NCES transplantation at the Fourth Affiliated Hospital of Soochow University between June 2023 and December 2024. Postoperatively, 36 lesions (from 7 patients) were treated with oral corticosteroids, and 34 lesions (from 5 patients) with upadacitinib, totaling 70 vitiligo lesions evaluated. Clinical efficacy and safety were assessed over a 6-month follow-up period. RESULTS: Both treatment groups showed similar mean repigmentation rates at 6 months. However, the distribution of responses differed. Patients treated postoperatively with JAK inhibitors demonstrated a more polarized pattern, while those receiving corticosteroids showed a more uniform distribution. Anatomical analysis revealed significantly better responses in the face and trunk compared to acral areas in both groups. Notably, JAK inhibitors showed potential advantages in traditional treatment-resistant regions such as the limbs. No serious adverse events were observed in either group. CONCLUSION: Both JAK inhibitors and corticosteroids appear to be safe and effective postoperative options following NCES. The choice of immunomodulatory strategy may influence repigmentation patterns, especially at different anatomical sites.
Effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects: a retrospective study.
Xu Y, Liu Y, Cao P … +5 more , Chen J, Li B, Wang Y, Zhang L, Liu S
J Dermatolog Treat · 2025 Dec · PMID 40798837 · Publisher ↗
OBJECTIVES: With the development of biotechnology, double-layer artificial dermis repair material has been increasingly employed to repair deep skin and soft tissue defects. This study aims to investigate the effectivene...
OBJECTIVES: With the development of biotechnology, double-layer artificial dermis repair material has been increasingly employed to repair deep skin and soft tissue defects. This study aims to investigate the effectiveness of double-layer artificial dermis repair material combined with autologous skin patch in repairing deep skin and soft tissue defects. METHODS: This study conducted a retrospective analysis of 18 patients with deep skin and soft tissue defects who were treated with a combination of double-layer artificial dermal repair materials and autologous skin grafting at our hospital between January 2022 and January 2024. RESULTS: A total of 18 patients were treated, including 7 males and 11 females, with an average age of 41.7 ± 19.12 years. All patients exhibited good vascularization of the double-layer artificial dermal material postoperatively. In one patient, only a small part of the autologous skin patch survived after the first grafting, and the skin healed well after the second grafting. The remaining patients healed well after the operation. Two months after the operation, the results showed that no obvious hyperplastic contracture scar was found in the wound grafts of 18 patients, and the total Vancouver Scar Scale (VSS) score was not significantly different between 1 month and 2 months after the operation ( 0.05). CONCLUSION: Double-layer artificial dermis repair material combined with autologous skin patch provides a reliable, less invasive and simple treatment for deep skin and soft tissue defects.
Vitiligo exacerbation during upadacitinib treatment for atopic dermatitis and improvement following a switch to abrocitinib: a case report.
Wang Z, Wang M, Sun Y
J Dermatolog Treat · 2025 Dec · PMID 40760904 · Publisher ↗
AIM: Janus kinase (JAK) inhibitors have emerged as targeted therapies for atopic dermatitis (AD), and increasing evidence suggests their potential benefit in vitiligo. While both diseases are considered immunologically d...
AIM: Janus kinase (JAK) inhibitors have emerged as targeted therapies for atopic dermatitis (AD), and increasing evidence suggests their potential benefit in vitiligo. While both diseases are considered immunologically distinct, recent insights point to overlapping cytokine pathways that may be modulated by JAK1-selective inhibitors. MATERIALS AND METHODS: We present a case of a 37-year-old male with moderate-to-severe AD and stable vitiligo who developed worsening of vitiligo following treatment with upadacitinib. Although AD symptoms resolved, vitiligo lesions progressed despite phototherapy. RESULTS: After switching from upadacitinib to abrocitinib, the patient experienced marked repigmentation of vitiligo lesions within three months, along with continued control of AD symptoms. CONCLUSIONS: This case highlights the differential effects of upadacitinib and abrocitinib, possibly due to their distinct JAK2 inhibition profiles. The findings underscore the importance of considering kinase selectivity when using JAK inhibitors in patients with overlapping immune-mediated skin disorders.
Levels of several inflammatory cytokines in acne patients before and after isotretinoin therapy: a randomized, controlled clinical trial.
Qi W, Wang R, Khasawneh SMS … +2 more , Hui F, Liu Y
J Dermatolog Treat · 2025 Dec · PMID 40739900 · Publisher ↗
INTRODUCTION: Acne vulgaris is a chronic inflammatory skin disease, and the inflammatory cytokines play a significant role in its pathophysiology. At present, oral isotretinoin is considered as the most effective treatme...
INTRODUCTION: Acne vulgaris is a chronic inflammatory skin disease, and the inflammatory cytokines play a significant role in its pathophysiology. At present, oral isotretinoin is considered as the most effective treatment for acne. However, its specific anti-inflammatory mechanisms are only partially understood. METHODS: The research included 75 patients with acne severity levels II, III and IV together with 25 healthy participants in this prospective controlled clinical trial. Patients received 20 mg/day oral isotretinoin for eight weeks. The research team evaluated inflammatory cytokine levels (IL-8, IL-36, TNF-α, TSLP, and TWEAK) at the beginning and end of the study. RESULTS: The levels of IL-8, IL-36, TNF-α, TSLP, and TWEAK were found to be significantly higher in acne patients as compared to controls ( < 0.05). IL-8, IL-36, and TWEAK levels were found to be significantly decreased after 8 weeks of isotretinoin treatment ( < 0.05). There was no correlation found between the severity of acne and inflammatory cytokine levels ( > 0.05). CONCLUSION: The anti-inflammatory effects of isotretinoin in acne patients result from its ability to decrease serum levels of inflammatory cytokines (IL-8, IL-36, TNF-α, TSLP, and TWEAK).
Upadacitinib in daily practice for refractory atopic dermatitis in adolescents: a case series of the BioDay registry.
Vroman F, van der Rijst LP, Bacoş-Cosma OI … +7 more , Zuithoff NPA, Kamsteeg M, van Lumig PPM, Loman L, Schuttelaar MLA, de Bruin-Weller MS, de Graaf M
J Dermatolog Treat · 2025 Dec · PMID 40739850 · Publisher ↗
PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice. MATERIALS AND METHODS: Fi...
PURPOSE: Upadacitinib is approved for treating moderate-to-severe atopic dermatitis (AD) aged ≥12 years. We evaluated upadacitinib's effectiveness and safety in AD adolescents in daily practice. MATERIALS AND METHODS: Fifteen adolescent AD patients from the BioDay registry, treated with upadacitinib 15 mg once daily were evaluated at baseline and after 4, 8, 16, and 28 weeks. Effectiveness was assessed using Eczema Area and Severity Index (EASI) score and Investigator Global Assessment (IGA) score. Patient-reported outcomes included Numeric Rating Scale (NRS) for pruritus and presence of sleep disturbance. Adverse events (AEs) were evaluated at each visit. RESULTS: Mean EASI score significantly decreased from 13.4 (95% CI 8.5-18.3) to 7.8 (95% CI 2.4-13.3) after 28 weeks ( = .002). Mean NRS pruritus significantly decreased from 6.5 (95% CI 4.9-8.2) to 4.8 (95% CI 3.0-6.6) after 28 weeks ( = .003). At week 16, 75.0% (95% CI 46.8-91.1) achieved EASI ≤7, and 50.0% (95% CI 25.4-74.6) achieved NRS pruritus ≤4. Overall, 31 AEs were reported in 10 patients (66.7%). Five patients (33.3%) discontinued treatment: two due to ineffectiveness, two due to AEs, and one due to laboratory monitoring problems. CONCLUSIONS: Our findings indicate that upadacitinib is effective and relatively safe for adolescents with moderate-to-severe AD; however, 33.3% discontinued treatment.
Family planning and pregnancy among patients with psoriasis: incorporating the patients' voice in healthcare practice and information provision.
Barenbrug L, van Ee I, van der Molen RG … +2 more , de Jong EMGJ, van den Reek JMPA
J Dermatolog Treat · 2025 Dec · PMID 40739803 · Publisher ↗
Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for th...
Having psoriasis and being treated with medication could raise concerns regarding family planning and pregnancy (FPP), and no guidelines are available on healthcare practice and information provision regarding FPP for these patients. This study aims to gain insight in the perspectives of patients with psoriasis on this important subject. A cross-sectional questionnaire study including adult female and male patients with psoriasis, independent of their treatment type. A total of 102 patients responded to the questionnaire (70% females, 30% males), of whom 47.1% have ever used biologic therapy. Respondents preferred dermatologists or general practitioners (GPs) as information provider. Patients would like to receive FPP information on fertility, heredity of psoriasis, use of psoriasis medication, and - specifically for females- the course of psoriasis during and after pregnancy and breastfeeding. Timing of FPP information provision was preferable at moment of diagnosis and medication changes or upon explicit request. Dermatologists and GPs have a crucial role in providing FPP information. The findings of this study have provided hands-on guidance for healthcare professionals to improve healthcare for both female and male patients with psoriasis in the reproductive age.
About
- Frequency
- Sun
- Papers found
- 200
- RSS feed
- Subscribe